Skip to main content

Table 1 Demographic and clinical characteristics of subjects

From: Comprehensive analysis of immunoglobulin and clinical variables identifies functional linkages and diagnostic indicators associated with Behcet’s disease patients receiving immunomodulatory treatment

  

BD-N

BD-C

BD-I

BD-C&I

HC

AAV

TA

N

15

12

8

28

66

/

/

Discovery set

Age(y)

35.40 ± 10.16

27.25 ± 13.18

30.50 ± 6.80

31.04 ± 9.800

49.17 ± 13.51

/

/

Sex(M/F)

10/5

7/5

4/4

20/8

31/35

/

/

ICBD

5.73 ± 2.63

5.75 ± 1.36

5.00 ± 1.53

6.643 ± 1.890

/

/

/

Validation set

N

27

5

16

/

30

18

18

Age(y)

37.81 ± 11.60

34.20 ± 12.40

36.94 ± 13.69

/

38.40 ± 11.40

51.89 ± 14.07

33.94 ± 10.46

Sex(M/F)

8/19

3/2

5/11

/

14/16

7/11

7/11

ICBD

5.19 ± 1.62

6.60 ± 0.89

5.50 ± 1.32

/

/

/

/

  1. BD-N BD patients not receiving corticosteroid or immunosuppressant treatment, BD-C BD patients receiving only corticosteroid treatment, BD-I BD patients receiving only immunosuppressant treatment, BD-C&I BD patients receiving both corticosteroid and immunosuppressant treatment